Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 7, 2018
Eisai announced today that the first investigational drug candidate from their drug discovery collaboration with University College London (UCL) is to enter Phase I clinical trials for Alzheimer's...
-
Dec 4, 2018-- In a real-world, observational, retrospective study of FYCOMPA as a first add-on therapy, 61% (19/31) of patients with generalized seizures achieved seizure freedom, with an overall retention rate of 85% (127/149) at 12 months
Eisai Inc. presented new data on FYCOMPA® (perampanel) CIII at the American Epilepsy Society Annual Meeting in New Orleans which included analyses of convulsive seizure freedom rates in adult and...
Nov 21, 2018Eisai Inc. today announced that it will present FYCOMPA® (perampanel) CIII long-term seizure freedom and pediatric data at the upcoming American Epilepsy Society Annual Meeting taking place from...
Oct 25, 2018Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”)...
-
Oct 24, 2018
Eisai Inc. the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that they have signed a value-based contract for FYCOMPA® (perampanel) CIII with Oklahoma Health Care Authority...
-
Oct 17, 2018Additional Data from BAN2401 Phase 2 Results to be Presented
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that five oral and two poster presentations from its Alzheimer's disease pipeline, including additional data on...
-
Oct 17, 2018Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy objectives
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced positive topline results from SUNRISE 2, a long-term Phase...
-
Oct 16, 2018Five scientific presentations and a video profiling new Eisai Center in Cambridge, Massachusetts to be presented at conference
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 5 poster presentations reporting new research on human genetics guided drug discovery will be highlighted at...
Oct 4, 2018- In secondary metabolic analyses of CAMELLIA-TIMI 61, patients with pre-diabetes who were treated with BELVIQ were less likely to develop diabetes and had a greater tendency to achieve normal blood glucose levels compared to patients treated with placeboEisai Inc. announced today new data on prevention and remission of diabetes from the CAMELLIA-TIMI 61 cardiovascular (CV) outcomes trial in patients treated with anti-obesity agent BELVIQ®...
-
Sep 28, 2018- FYCOMPA is an important new option for pediatric patients to potentially improve seizure control
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug FYCOMPA® (perampanel) CIII for monotherapy and adjunctive use in...
-
Aug 27, 2018- CAMELLIA-TIMI 61 is first large-scale outcomes trial to achieve long-term cardiovascular (CV) safety for a weight loss agent
Eisai Inc. announced today that results from the CAMELLIA-TIMI 61 cardiovascular (CV) outcomes trial in patients treated with BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily were presented at the...
-
Jul 25, 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
Jul 25, 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
Jul 18, 2018Thirteen presentations to be given including late breaking Phase 2 study results of BAN2401 and elenbecestat
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 13 posters and presentations from its robust Alzheimer's disease pipeline, including the Phase 2 clinical...
-
Jul 17, 2018- BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients
Eisai Inc. announced positive topline results from the CAMELLIA-TIMI 61 cardiovascular outcome trial. This 12,000 patient study of BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily was conducted at...
Jul 9, 2018Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today the results of the BAN2401 Phase II clinical study, Study 201(ClinicalTrials.gov identifier NCT01767311), will be...
-
Jul 5, 2018- The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer's disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
Jul 2, 2018Presentation includes data from first-ever Phase 3 head-to-head superiority comparison vs zolpidem ER in patients with a sleep-wake disorder
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced that they will present data on their investigational...
-
Jun 5, 2018Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their...
-
Jun 5, 2018RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
May 30, 2018- Designation underscores the need to expand potential treatment options to help certain young patients achieve goal of seizure freedom
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for its antiepileptic drug FYCOMPA®...
-
May 22, 2018
Companies will present data on: Postural stability after middle-of-the-night awakening and next-morning compared to zolpidem ER Auditory awakening threshold Return to sleep latency compared to...
-
Apr 19, 2018Abstracts presented add to growing body of FYCOMPA data supporting convulsive seizure freedom, and real-world, long-term safety & efficacy data
Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include...
-
Mar 30, 2018- First step to making FYCOMPA available for children, underscoring Eisai's commitment to epilepsy care for patients of all ages
Eisai Inc. announced today that it has submitted a supplemental New Drug Application (sNDA) for priority review to the U.S. Food and Drug Administration (FDA) for its antiepileptic drug FYCOMPA®...
-
Mar 7, 2018
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today announced positive topline results from multiple studies of lemborexant,...
-
Jan 30, 2018
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer's disease-associated genetic variants on the behavior of brain cells,...
-
Dec 6, 2017seizures and healthcare utilization associated with perampanel therapy
Eisai Inc. presented eight posters on perampanel (marketed as FYCOMPA® CIII) at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. The poster presentations included analyses...
Dec 5, 2017Tools now available to help adolescents with epilepsy transition to the adult health care system underscoring Eisai's leadership and commitment to the epilepsy communityThe Child Neurology Foundation (CNF) and Eisai today announced the availability of original resources aimed at helping those living with epilepsy navigate and simplify the transition from their...
-
Nov 22, 2017Data of note includes post-hoc analysis identifying potential predictors of major response to treatment with perampanel
Eisai Inc. announced today the presentation of eight posters on data, including real-world use of perampanel (marketed as FYCOMPA® CIII). These data will be presented at the American Epilepsy...
-
Oct 30, 2017
Eisai Inc. announced today the presentation of three posters during the 10th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting, highlighting data on innovative ways to screen for...
-
Jul 26, 2017- First antiepileptic drug (AED) to apply FDA's regulatory pathway of extrapolation for monotherapy use; FDA proposed using this pathway to get monotherapy options to patients sooner
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for FYCOMPA® (perampanel) CIII as monotherapy use...
-
Jul 17, 2017
Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease portfolio, at the Alzheimer's Association International...
-
Jun 21, 2017Lorcaserin Phase IIIb/IV Outcomes Study Assesses Incidence of Major Adverse Cardiovascular Events (MACE) in Patients with Overweight or Obesity
Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as planned, based on the recommendation of an independent...
-
Apr 27, 2017Data to be Presented at the American Academy of Neurology "Best Of" Epilepsy Session
Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive antiepileptic drug (AED) treatment versus placebo...
-
Apr 13, 2017Eisai Announces Perampanel Data in Epilepsy at the 2017 American Academy of Neurology Annual MeetingMeta-analysis on the extrapolation of adult antiepileptic drug efficacy data, including perampanel, to pediatric patients to be featured in "Best Of" oral presentation panel
Eisai Inc. announced today that eight poster presentations featuring data on the safety and efficacy of perampanel (marketed as FYCOMPA® CIII) in a range of seizure types will be presented at the...
Mar 23, 2017Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the Epilepsy Foundation's National Walk for Epilepsy on...
Jan 4, 2017Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (collectively, "Eisai"), announced today that it has reached an agreement with Arena Pharmaceuticals, Inc. to revise the November...
- Dec 19, 2016
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health...
Dec 12, 2016Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest data on elenbecestat (development code: E2609), its...
- Dec 5, 2016Presentations Include Analysis of Real-World Use and Post-Hoc Analysis of Long-Term Safety and Efficacy
Eisai Inc. announced today new analyses and data on perampanel presented at the 2016 Annual Meeting of the American Epilepsy Society (AES). Perampanel, marketed as FYCOMPA® CIII, is indicated as...
- Dec 5, 2016
Eisai Inc. announced today final results of its Phase 3 open-label two-year study of rufinamide, which were presented at the 2016 Annual Meeting of the American Epilepsy Society (AES) held from...
- Nov 28, 2016
Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data from the company's anti-epileptic drugs FYCOMPA®...
-
Nov 17, 2016
Eisai Inc. announced today that it has received U.S. Food and Drug Administration (FDA) Fast Track designation for the development of E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor...
- Nov 3, 2016
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin...
-
Oct 31, 2016
Eisai Inc. and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study (Study 202) to evaluate Eisai's internally-discovered oral dual orexin...
- Oct 31, 2016
Eisai Inc. announced today that enrollment has begun in the U.S. for MISSIONAD, a Phase 3 clinical program for E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor for patients with early...
- Oct 28, 2016Trials to assess perampanel in those with Lennox-Gastaut Syndrome, a rare form of epilepsy, and in children with partial-onset seizures now enrolling patients
Eisai Inc. announced today the initiation of two multi-center, global Phase 3 clinical trials assessing FYCOMPA® (perampanel) CIII in two different patient populations: patients age 2 years and...
- Oct 26, 2016"Medikidz Explain LGS," endorsed by leading advocacy groups, educates public on rare and severe form of epilepsy
Eisai Inc. today announced the launch of "Medikidz Explain Lennox-Gastaut Syndrome (LGS)," an educational comic book designed to inform people about LGS, a rare type of epilepsy that is usually...
- Oct 3, 2016New FDA-Approved Formulation Offers Patients a Once-Daily Dosing Option for Chronic Weight Management
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that...
- Sep 26, 2016Application Based on New FDA Communication Supporting Use as Monotherapy for the Treatment of Partial Onset Seizures Based on Extrapolation
Eisai Inc. announced today that it has submitted a supplemental application to the U.S. Food and Drug Administration (FDA) for a proposed label change for its antiepileptic drug FYCOMPA®...
